Literature DB >> 17504991

The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.

Caroline Pabst1, Holger Schirutschke, Gerhard Ehninger, Martin Bornhäuser, Uwe Platzbecker.   

Abstract

PURPOSE: Recently, high numbers of regulatory T cells within the stem cell graft were described to be associated with less graft-versus-host disease (GVHD) after related peripheral blood stem cell transplantation (PBSCT). Studies in mice also suggest a distinct role of gamma delta TCR(+) T cells in mediating GVHD. Therefore, the aim of this study was to define the yet-unknown role of regulatory and gamma delta TCR(+) T cells in human PBSCT from unrelated donors. EXPERIMENTAL
DESIGN: The frequency of both T-cell subsets within the graft was analyzed in 63 patients receiving unrelated allogeneic PBSCT. The respective amounts were quantified by flow cytometry and PCR and further correlated with clinical outcome.
RESULTS: The grafts contained a median of 11.2 x 10(6)/kg CD4(+)foxp3(+) and 9.8 x 10(6)/kg gamma delta TCR(+) T cells, respectively. Patients receiving more CD4(+)foxp3(+) cells had a lower cumulative incidence of acute GVHD II-IV (44% versus 65%, P=0.03). Interestingly, in patients who received higher concentrations of donor gamma delta TCR(+) T cells, acute GVHD II-IV was more frequent (66% versus 40%, P=0.02). In multivariate analysis, only the graft concentration of gamma delta TCR(+) T cells (P=0.002) and a positive cytomegalovirus status of the recipient (P = 0.03) were significantly associated with the occurrence of acute GVHD II-IV.
CONCLUSION: Graft composition of T-cell subsets seems to affect the outcome of patients receiving allogeneic PBSCT from unrelated donors. Therefore, selective manipulation or add-back of particular subsets might be a promising strategy to reduce the incidence of GVHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504991     DOI: 10.1158/1078-0432.CCR-06-2602

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  T regulatory cells maintain intestinal homeostasis by suppressing γδ T cells.

Authors:  Sung-Gyoo Park; Ramkumar Mathur; Meixiao Long; Namiko Hosh; Liming Hao; Matthew S Hayden; Sankar Ghosh
Journal:  Immunity       Date:  2010-11-11       Impact factor: 31.745

3.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.

Authors:  James D Lord; Robert C Hackman; Ted A Gooley; Brent L Wood; Amanda C Moklebust; David M Hockenbery; Gideon Steinbach; Steven F Ziegler; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

Review 4.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

5.  γδ T lymphocytes kill T regulatory cells through CD1d.

Authors:  Sally A Huber
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

6.  Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.

Authors:  Lucas C M Arruda; Ahmed Gaballa; Michael Uhlin
Journal:  Blood Adv       Date:  2019-11-12

Review 7.  Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.

Authors:  Michael R Verneris
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 8.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

9.  Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells.

Authors:  Brian G Engelhardt; James E Crowe
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

10.  Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.

Authors:  Matthew Horch; Vu H Nguyen
Journal:  Ther Adv Hematol       Date:  2012-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.